Managing weight and blood sugar is a daily challenge for many people living with type 2 diabetes or obesity. New evidence looks at the effectiveness of oral small-molecule GLP-1 receptor agonists, which are medications designed to mimic a hormone that regulates appetite and insulin.
The data shows these oral medications significantly reduce body weight, body mass index, and waist circumference. They also effectively lower fasting blood glucose levels and HbA1c, which is the standard measure of average blood sugar over several months. Specifically, patients taking these drugs were much more likely to achieve significant weight loss goals of 5%, 10%, or even 15%.
While these medications offer clear benefits for weight and sugar control, they do come with some trade-offs. The study found a higher risk of gastrointestinal issues, such as nausea, vomiting, diarrhea, and constipation. However, there was no increase in serious adverse events reported. These findings suggest that while the oral versions are effective tools, patients should talk to their doctor about managing potential stomach side effects.
